Scentech Medical

What Scentech Medical does

Scentech Medical is a Tel Aviv, Israel-based private health care technology company founded in 2018 that develops AI-driven breath analysis technology to identify cancer and infectious diseases. The company's core product analyzes volatile organic compounds and other biomarkers present in exhaled breath samples, using artificial intelligence to generate medical diagnostic insights intended to support clinical decision-making. The platform operates as a standalone AI-powered diagnostic technology, processing breath input data to produce health insights. No pricing model, go-to-market strategy, customer segments, or disclosed revenue are available in the source data.

With a headcount of 1-10 employees and no publicly disclosed customers or commercial partnerships beyond its parent entity relationship, Scentech Medical appears to be at a pre-commercial or early-commercial stage. On 2026-01-28, Reliance Global Group, Inc. (NASDAQ:EZRA) announced plans to acquire a majority stake in Scentech Medical Technologies through its newly formed Ezra International Group. This transaction represents Scentech Medical's integration into Reliance's Scale 51 technology investment initiative and marks the company's transition into a strategic portfolio position rather than an independent commercialization path.

Name

Scentech Medical

Website

https://scent.tech

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Scentech Medical is a Tel Aviv-based health technology company developing AI-driven breath analysis technology to identify cancer and infectious diseases through volatile organic compound analysis in exhaled breath samples.

Ownership category

akta.pro rank

Product category

Medical Diagnostics Software

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers) (HLAHAGAK)

Keywords

• Breath analysis diagnostics
• AI medical diagnostics
• Non-invasive disease detection
• Volatile organic compound analysis
• Cancer screening technology

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Core offering

Scentech Medical Technologies develops an AI-driven breath analysis platform that analyzes volatile organic compounds and biomarkers in exhaled breath to generate medical diagnostic insights for cancer and infectious diseases. The platform uses generative AI to process breath samples and produce clinical decision-support outputs for healthcare providers and clinical research applications.

Product overview

Scentech Medical Technologies is a single core product offering focused on AI-driven breath analysis for medical diagnostics. The company analyzes volatile organic compounds and other biomarkers in exhaled breath using artificial intelligence to generate health diagnostic insights. The product operates as a standalone AI-powered diagnostic technology platform.

Differentiator

Problem solved

Functional benefit

Products and services

• Scentech Medical Technologies AI Breath Analysis Platform An AI-driven breath analysis platform that analyzes volatile organic compounds and biomarkers in exhaled breath to generate medical diagnostic insights for cancer and infectious diseases. Built for healthcare providers, clinical laboratories, and clinical research institutions seeking non-invasive diagnostic tools.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Recent moves3 records

Expansion highlights3 records

Direct peers

• Owlstone Medical: A leading breath-biopsy company developing VOC-based diagnostics for cancer and other diseases; the most directly comparable company to Scentech in target indications and technology approach (breath-based biomarker analysis).
• Menssana Research: Develops BreathLink and related non-invasive breath tests for diseases including lung cancer and infectious diseases; competes in the same niche of AI/analytical breath diagnostics.

Emerging players

• Avisa Pharma: Clinical-stage company developing a breath-based biomarker test for rapid detection of bacterial lung infection; an emerging peer intersecting with Scentech's infectious-disease application area.
• Cambridge Respiratory Innovations: Develops respiratory diagnostic devices including breath-based monitoring tools (e.g., N-Tidal) suitable for COPD and other chronic conditions, offering overlapping diagnostic technology roots.
• Diagnostics.ai: AI-driven diagnostics company developing algorithms for clinical laboratory and infectious-disease testing — a comparable AI-in-diagnostics peer where the AI layer resembles Scentech's generative-AI approach even though the input modality differs.

Broad incumbents

• Tempus Labs: Large AI-driven precision medicine and diagnostics company; overlaps with Scentech's goal of using AI to interpret complex biomarker/clinical data for disease detection, though not breath-focused.
• PathAI: AI-enabled diagnostics company focused on pathology; a comparable AI-in-diagnostics peer even though the input modality (tissue vs. breath) differs.
• ResMed: Global medical device leader in respiratory monitoring and ventilation; provides adjacent reference points for respiratory gas-related hardware, though focused on therapy rather than breath diagnostics.
• Philips Respironics: Incumbent in respiratory care, ventilation, and sleep diagnostics; comparable through its portfolio of respiratory gas- and airway-interfacing devices, even though its core focus is therapy rather than breath-based disease detection.

Others

• Apieron (formerly Aerocrine / Circassia-era assets): Historical precedent in exhaled-breath diagnostic devices (e.g., fractional exhaled nitric oxide for asthma); a thematic reference point for the regulatory and commercial pathway Scentech is pursuing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scentech Medical